Steven R. Olsen

5.9k total citations · 1 hit paper
23 papers, 4.0k citations indexed

About

Steven R. Olsen is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Steven R. Olsen has authored 23 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 7 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Steven R. Olsen's work include HER2/EGFR in Cancer Research (11 papers), Cancer Treatment and Pharmacology (7 papers) and Breast Cancer Treatment Studies (4 papers). Steven R. Olsen is often cited by papers focused on HER2/EGFR in Cancer Research (11 papers), Cancer Treatment and Pharmacology (7 papers) and Breast Cancer Treatment Studies (4 papers). Steven R. Olsen collaborates with scholars based in United States, Canada and France. Steven R. Olsen's co-authors include Ellie Guardino, Fang Ting Liang, Véronique Dièras, Mark D. Pegram, Sunil Verma, Do‐Youn Oh, Ian E. Krop, David Miles, Luca Gianni and Michael W. Lu and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Steven R. Olsen

23 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

2012 2.7k citations Sunil Verma, David Miles et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Steven R. Olsen

Since Specialization

Citations

This map shows the geographic impact of Steven R. Olsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven R. Olsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven R. Olsen more than expected).

Fields of papers citing papers by Steven R. Olsen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven R. Olsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven R. Olsen. The network helps show where Steven R. Olsen may publish in the future.

Co-authorship network of co-authors of Steven R. Olsen

This figure shows the co-authorship network connecting the top 25 collaborators of Steven R. Olsen. A scholar is included among the top collaborators of Steven R. Olsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven R. Olsen. Steven R. Olsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pertuzumab plus trastuzumab and real-world standard of care (SOC) for patients (pts) with treatment refractory metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) confirmed by tumor tissue or ctDNA analysis (TRIUMPH, EPOC1602). 2021 ·Journal of Clinical Oncology ·Wataru Okamoto, Yoshiaki Nakamura, Takeshi Kato, Taito Esaki, Masato Komoda, Ken Kato, Yoshito Komatsu, Toshiki Masuishi, Tomohiro Nishina, Kentaro Sawada, Hiroya Taniguchi, Nozomu Fuse, Shogo Nomura, Makoto Fukui, Steven R. Olsen, Justin I. Odegaard, Akihiro Sato, Satoshi Fujii, Atsushi Ohtsu, Takayuki Yoshino	12
2	Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy 2013 ·Clinical Cancer Research ·Gail D. Lewis Phillips, Carter T. Fields, Guangmin Li, Donald Dowbenko, Gabriele Schaefer, Kathy D. Miller, Fabrice André, Howard A. Burris, Kathy S. Albain, Nadia Harbeck, Véronique Dièras, Diana Crivellari, Fang Ting Liang, Ellie Guardino, Steven R. Olsen, Lisa Crocker, Mark X. Sliwkowski	148
3	Differential expression of microRNAs induced by trastuzumab emtansine (T-DM1) during megakaryocytopoiesis. 2013 ·Journal of Clinical Oncology ·Hirdesh Uppal, (unknown), Sock-Cheng Lewin-Koh, Steven R. Olsen, Mark X. Sliwkowski, Sandhya Girish, Dylan P. Hartley, Donna M. Dambach, Vanitha Ramakrishnan	1
4	Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer breakdown → 2012 ·New England Journal of Medicine ·Sunil Verma, David Miles, Luca Gianni, Ian E. Krop, Manfred Welslau, José Baselga, Mark D. Pegram, Do‐Youn Oh, Véronique Dièras, Ellie Guardino, Fang Ting Liang, Michael W. Lu, Steven R. Olsen, Kim T. Blackwell	2665
5	Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. 2012 ·Journal of Clinical Oncology ·Kimberly Blackwell, David Miles, Luca Gianni, Ian E. Krop, Manfred Welslau, José Baselga, Mark D. Pegram, Do‐Youn Oh, Véronique Dièras, Steven R. Olsen, Fang Ting Liang, Michael W. Lu, Ellie Guardino, Sunil Verma	66
6	Results from Emilia, A Phase 3 Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine (X) and Lapatinib (L) in Her2-Positive Locally Advanced or Metastatic Breast Cancer (MBC) 2012 ·Annals of Oncology ·Sunil Verma, David Miles, Lorenzo Gianni, IE Krop, Manfred Welslau, José Baselga, M. Pegram, Do‐Youn Oh, Véronique Dièras, Ellie Guardino, Fang Ting Liang, (unknown), Steven R. Olsen, (unknown)	2
7	Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. 2012 ·Journal of Clinical Oncology ·Kimberly Blackwell, David Miles, Luca Gianni, Ian E. Krop, Manfred Welslau, José Baselga, Mark D. Pegram, Do‐Youn Oh, Véronique Dièras, Steven R. Olsen, (unknown), Michael W. Lu, Ellie Guardino, Sunil Verma	29
8	The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial 2009 ·Breast Cancer Research and Treatment ·Evandro de Azambuja, Worta McCaskill‐Stevens, Prudence A. Francis, Emmanuel Quinaux, John Crown, (unknown), Rosa Giuliani, Bo Nordenskjöld, (unknown), Michael Andersson, Mireia Margelí Vila, R. Jakesz, Jan Demol, Joanna Dewar, Armando Santoro, Aňa Lluch, Steven R. Olsen, Richard D. Gelber, Angelo Di Leo, Martine Piccart	128
9	Homeopathy for Menopausal Symptoms in Breast Cancer Survivors: A Preliminary Randomized Controlled Trial 2005 ·The Journal of Alternative and Complementary Medicine ·Jennifer Jacobs, Patricia M. Herman, (unknown), Steven R. Olsen, (unknown)	70
10	Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer 2005 ·Annals of Oncology ·William J. Gradishar, Suparna Wedam, Mohammad Jahanzeb, John K. Erban, Steven Limentani, (unknown), Steven R. Olsen, Sandra M. Swain	32
11	Taxanes and COX-2 inhibitors: from molecular pathways to clinical practice 2005 ·Biomedicine & Pharmacotherapy ·Steven R. Olsen	24
12	Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer 2005 ·Journal of Clinical Oncology ·Stephen E. Jones, John K. Erban, Beth Overmoyer, G. T. Budd, Laura F. Hutchins, EE Lower, Leslie Rodgers Laufman, (unknown), W J Urba, Kathleen I. Pritchard, Robert Mennel, Donald Richards, Steven R. Olsen, (unknown), Peter M. Ravdin	419
13	Topoisomerase II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated with single-agent doxorubicin or single-agent docetaxel 2004 ·Cancer Research ·Christine Desmedt, Virginie Durbecq, Marianne Paesmans, Christos Sotiriou, Jean-Yves Leroy, Ghizlane Rouas, Stephen Chan, Kay Friedrichs, Tamás Pintér, Sebastian Belle, Elizabeth Murray, (unknown), Steven R. Olsen, Angelo Di Leo, Fátima Cardoso, Martine Piccart, Denis Larsimont	40
14	Glucocorticoid Regulation of Natural Cytotoxicity: Effects of Cortisol on the Phenotype and Function of a Cloned Human Natural Killer Cell Line 1997 ·Cellular Immunology ·Jie Zhou, Steven R. Olsen, John B. Moldovan, (unknown), Fazlul H. Sarkar, V.K. Moudgil, Denis M. Callewaert	56
15	Glutamic acid 203 of the cAMP-dependent protein kinase catalytic subunit participates in the inhibition by two isoforms of the protein kinase inhibitor. 1994 ·Journal of Biological Chemistry ·Eric J. Baude, (unknown), Steven R. Olsen, Erwin M. Reimann, Michael D. Uhler	13
16	Binding of a cementum attachment protein to extracellular matrix components and to dental surfaces 1992 ·Journal of Periodontal Research ·S. Pitaru, Naphtali Savion, (unknown), Steven R. Olsen, Sampath Narayanan	25
17	Inhibition of Protein Kinase-A by Overexpression of the Cloned Human Protein Kinase Inhibitor 1991 ·Molecular Endocrinology ·Steven R. Olsen, Michael D. Uhler	49
18	Isolation and characterization of cDNA clones for an inhibitor protein of cAMP-dependent protein kinase 1991 ·Journal of Biological Chemistry ·Steven R. Olsen, Michael D. Uhler	56
19	Affinity Purification of the Cα and Cβ Isoforms of the Catalytic Subunit of cAMP-dependent Protein Kinase 1989 ·Journal of Biological Chemistry ·Steven R. Olsen, Michael D. Uhler	56
20	Effects of CI-914 in congestive heart failure due to coronary artery disease or idiopathic cardiomyopathy 1986 ·The American Journal of Cardiology ·(unknown), Patrick D.V. Bourdillon, David Cheng, (unknown), Steven R. Olsen, John M. Nicklas, Bertram Pitt	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact